David Stein heads up a consortium behind technology that can produce diagnostic results from small capillary consumer samples collected in retail locations. Here, amid the hype and misdirection of Theranos, he speaks to Health Tech World correspondent Gil Bashe on the why, when and how of delivering diagnostic data from drops of blood.
David Stein is leading a consortium of companies – Siemens, Becton Dickinson and Roche Diagnostics – that has developed the technology to deliver diagnostic results from small capillary consumer samples collected at retail locations.
Stein, formerly president of Siemens Healthineers Molecular Diagnostics and ex-CEO of the Siemens Point of Care, is now CEO of Babson Diagnostics.
His clinical successes counters the false narrative spread by Elizabeth Holmes and Theranos. Her hype and oversell resulted in books, major media op eds and a soon-to-be produced movie – and a major criminal investigation.
David is among the most knowledgeable expert to explain whether the Theranos hype to deliver diagnostic data from drops of blood is possible and, if so, why and how.
Click play below to listen to the interview.